Coeptis Therapeutics (NASDAQ:ZSQR) Releases Earnings Results

Coeptis Therapeutics (NASDAQ:ZSQR) posted its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, Zacks reports. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Coeptis Therapeutics Price Performance

NASDAQ ZSQR opened at $4.16 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The stock’s fifty day moving average price is $8.42 and its 200 day moving average price is $10.79. Coeptis Therapeutics has a 1 year low of $3.77 and a 1 year high of $21.41. The company has a market cap of $213.95 million, a price-to-earnings ratio of -1.65 and a beta of -0.20.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Trading of Coeptis Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its holdings in shares of Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the period. Marshall Wace LLP acquired a new stake in shares of Coeptis Therapeutics during the fourth quarter worth about $259,000. State Street Corp boosted its position in Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.